Evidence map›Paper›PMID 41390302›Full record

ArticleAnnals of the rheumatic diseases2026

Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality.

Yann L C Becker, Éric Boilard, Emmanuelle Rollet-Labelle, Christian Lood, Anne-Sophie Julien, Michal Abrahamowicz, Isabelle Allaeys, May Choi, Joannie Leclerc, Tania Lévesque and 33 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Yann L C BeckerCentre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.
Éric BoilardCentre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.
Emmanuelle Rollet-LabelleCentre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.
Christian LoodDivision of Rheumatology, University of Washington, Seattle, WA, USA.
Anne-Sophie JulienDepartment of Mathematics and Statistics, Université Laval, Québec City, QC, Canada.
Michal AbrahamowiczDepartment of Epidemiology & Biostatistics, McGill University, Montréal, Québec City, QC, Canada.
Isabelle AllaeysCentre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.
May ChoiDivision of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Joannie LeclercCentre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada.
Tania LévesqueCentre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.
Murray UrowitzUniversity of Toronto, Toronto Western Hospital, University Health Network, Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada.
John G HanlyDivision of Rheumatology, Department of Medicine, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada.
Caroline GordonRheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Sang-Cheol BaeDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang Institute of Bioscience and Biotechnology, Seoul, Republic of Korea.
Juanita Romero-DiazInstituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico; University of Manitoba, Winnipeg, MB, Canada.
Jorge Sanchez-GuerreroUniversity of Toronto, Toronto Western Hospital, University Health Network, Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada; Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Ann E ClarkeDivision of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Sasha BernatskyDepartment of Epidemiology & Biostatistics, McGill University, Montréal, Québec City, QC, Canada; Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
Daniel WallaceCedars Sinai Medical Center, Los Angeles, CA, USA.
David IsenbergCentre for Rheumatology, Department of Medicine, University College London, London, UK.
Anisur RahmanCentre for Rheumatology, Department of Medicine, University College London, London, UK.
Joan MerrillOklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Dafna D GladmanUniversity of Toronto, Toronto Western Hospital, University Health Network, Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada.
Ian N BruceCentre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK; Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, UK.
Michelle PetriDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ellen GinzlerDepartment of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Mary Anne DooleyRaleigh Neurology Associates, Raleigh, NC, USA.
Rosalind Ramsey-GoldmanNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Susan ManziAllegheny Health Network, Lupus Center of Excellence, Pittsburgh, PA, USA.
Andreas JönsenDepartment of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden.
Graciela S AlarcόnMarnix E. Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Ronald van VollenhovenAmsterdam University Medical Centers, Amsterdam, The Netherlands.
Cynthia AranowFeinstein Institutes for Medical Research, Manhasset, NY, USA.
Guillermo Ruiz-IrastorzaBiobizkaia Health Research Institute, UPV/EHU, Barakaldo, País Vasco, Spain.
Sam LimEmory University, Atlanta, GA, USA.
Murat InancDivision of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Kenneth KalunianUniversity of California San Diego, San Diego, CA, USA.
Soren JacobsenRigshospitalet, Copenhagen, Denmark.
Christine PeschkenUniversity of Manitoba, Winnipeg, MB, Canada.
Diane KamenMedical University of South Carolina, Charleston, SC, USA.
Anca AskanaseColumbia University Medical Center, New York, NY, USA.
Jill BuyonNew York University Grossman School of Medicine, New York, NY, USA.
Paul R FortinCentre de Recherche ARThrite-Université Laval, Quebec City, QC, Canada; Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada; Division of Rheumatology, Department of Medicine, CHU de Québec - Université Laval, Quebec City, QC, Canada. Electronic address: Paul.Fortin@crchudequebec.ulaval.ca.

Funding

Role of mitochondria in SLE and its cardiovascular complicationsR01HL158606 · NHLBI · UNIVERSITY OF WASHINGTON · PI LOOD, JAN CHRISTIAN · 2021 to 2025
$2.8M
Extracellular mitochondria in Inclusion Body MyositisR21AR079542 · NIAMS · UNIVERSITY OF WASHINGTON · PI LOOD, JAN CHRISTIAN · 2021 to 2021
$463k
Mitochondrial calcification in juvenile dermatomyositisR21AR077565 · NIAMS · UNIVERSITY OF WASHINGTON · PI LOOD, JAN CHRISTIAN · 2020 to 2021
$432k
NHLBI NIH HHS R01 HL158606NIAMS NIH HHS R21 AR077565NIAMS NIH HHS R21 AR079542
6 · The paper itself

Abstract

objectivesSystemic lupus erythematosus (SLE) remains a deadly disease, yet our ability to predict adverse outcomes is poor. Mitochondria are organelles recognised by the immune system when released from cells, and antimitochondrial antibodies (AMA) can be detected in people with SLE. We assessed AMA as markers of nephritis, arterial vascular events (AVE), and other outcomes including mortality.

methodsWe studied sera and data from 1114 participants of the Systemic Lupus International Collaborating Clinics inception cohort. We measured antiwhole mitochondria (AwMA), antimitochondrial DNA (AmtDNA), and antimitochondrial RNA (AmtRNA) antibodies by direct Enzyme-Linked ImmunoSorbent Assays (ELISAs). Separate multivariable Cox proportional hazards regression models estimated associations of either baseline or most recent measures of AMA with the outcomes, adjusted for biological sex, age, medications, and other clinical factors. Interactions of AMA with biological sex were tested for each outcome.

resultsAll AMA titres were elevated in SLE vs healthy individuals. Higher AMA levels were associated with a higher hazard of nephritis, with the strongest associations for most recent AmtDNA (adjusted hazard ratio [aHR] =1.61 for increase of 1 SD, 95% CI 1.43-1.82) and AmtRNA (aHR =1.59, 1.46-1.73). Higher baseline AwMA levels predicted early mortality (aHR =1.19, 1.02-1.40). Most recent AmtDNA (aHR =1.68, 1.28-2.19) was associated with higher mortality throughout the follow-up. For AVE, the impact of higher AmtRNA was stronger in females.

conclusionsBaseline and most recent assessments of AMA levels may help identify individuals at higher risk of severe outcomes in SLE, including mortality. Integrating AMA into precision medicine strategies will allow deeper exploration of lupus heterogeneity.

Indexed as

AutoantibodiesLupus Erythematosus, SystemicLupus NephritisMitochondriaAdultBiomarkersDNA, MitochondrialFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsAutoantibodiesBiomarkersDNA, Mitochondrial

Identifiers

PMID41390302
PMCPMC13616215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.